Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (18)	5/19/2001 12:20:02 PM
From: tuck	Respond to of 269

Rick, Time to add audio to your backlog: Many companies we are interested in presented at CIBC's new conference (hosted by a gushing Matt Geller). VGNX among them. Thanks to rkrw for the pointer. Probably some redundancy with recent earnings CCs, but . . . cibc.talkpoint.com Cheers, Tuck

To: scaram(o)uche who wrote (18)	6/28/2001 2:26:05 AM
From: tuck	Respond to of 269

Not sure what a "hap map" from CRA and from the Collins/Lander crew means to VGNX. It will be produced so far in the future that it likely means nothing. Anyhow, Venter says he and CRA will again go their own way in producing one. genomeweb.com Cheers, Tuck

To: scaram(o)uche who wrote (18)	6/29/2001 12:56:42 PM
From: scaram(o)uche	Respond to of 269

Friday June 29, 12:51 pm Eastern Time Press Release Illumina Signs Genotyping Services Agreement With GlaxoSmithKline SNP Scoring Service to Leverage Illumina's BeadArray Platform Technology SAN DIEGO--(BW HealthWire)--June 29, 2001--Illumina, Inc. announced today that it has signed a commercial agreement with GlaxoSmithKline (GSK) to provide single nucleotide polymorphism (SNP) genotyping services on a sample collection provided by GSK. Under the terms of the agreement, Illumina will use its BeadArray(TM) technology to ``score,'' or determine the frequency of specified SNPs in the sample set. Further details were not disclosed. (snip) Friday June 29, 2:00 am Eastern Time Press Release SOURCE: Orchid BioSciences, Inc. Orchid Completes First Major Milestone for AstraZeneca PRINCETON, N.J., June 29 /PRNewswire/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - news) today announced that it has successfully completed the first milestone in its multi-year genotyping and pharmacogenetics collaboration with AstraZeneca, resulting in a significant payment to Orchid. Further financial details were not disclosed. Using the SNPcode(TM) technology that combines Orchid's proprietary SNP-IT(TM) biochemistries with the GenFlex(TM) chip and GeneChip® system of Affymetrix, Orchid rapidly developed assays and conducted genotyping for the first cohort of samples provided by AstraZeneca. In a significant concordance study to validate the overall accuracy and reproducibility of the technology, Orchid has also exceeded all of the targets established for the first phase of the program. Based on these positive results, Orchid and AstraZeneca are now proceeding to the next phase of the collaboration. (snip)